Worth reading
73In focus
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
102095756000
Yen (total public offering issue price)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Public offering of new shares (general offering), issuance of new shares through a third-party allotment, and offering of shares (offering through an over-allotment)
発行・処分する株式数
Public offering of new shares: 51,304,400 shares (domestic general offering: 21,804,400 shares; international offering: 29,500,000 shares). Issuance of new shares through a third-party allotment: 7,695,600 shares (maximum). Offering of shares: 7,695,600 shares
Intended allottee
Public offering: domestic underwriters and international underwriters. Third-party allotment: Not disclosed
Public offering issue price: ¥1,990 per share. Third-party allotment payment amount: ¥1,907.08 per share. Offering price: ¥1,990 per share
Total issue value
Public offering: ¥102,095,756,000. Third-party allotment: ¥14,676,124,848 (maximum)
Amount of funds to be raised
Total payment amount: public offering ¥97,841,595,152; third-party allotment ¥14,676,124,848 (maximum). Total estimated net proceeds: ¥111,565,720,000 (maximum)
Specific use of funds
Research and development in oncology, primarily clinical trials for enzomenib and nuvisertibAmount ¥30,000 million / Scheduled timing of expenditures By the end of March 2029
Research and development in neurodegenerative diseases and infectious diseasesAmount ¥10,000 million / Scheduled timing of expenditures By the end of March 2029
Investments and loans to RACTHERA and S-RACMOAmount ¥10,000 million / Scheduled timing of expenditures By the end of March 2029
Strategic investments in capital expenditures to strengthen production and quality systems, IT systems, and partnerships and licensing agreements relating to the development and sale of products manufactured by other companiesAmount ¥10,000 million / Scheduled timing of expenditures By the end of March 2029
Repayment of interest-bearing debtAmount Remaining amount / Scheduled timing of expenditures By the end of March 2029
発行済株式総数
Issuance of 51,304,400 new shares through the public offering and 7,695,600 new shares through the third-party allotment (maximum)
Offering structure
Underwriter / lead underwriter
Domestic underwriters and international underwriters (individual names: Not disclosed)
Overallotment
Shares offered: 7,695,600 shares. Maximum number of shares under the third-party allotment: 7,695,600 shares
Payment date
Public offering: 24 April 2026. Third-party allotment: 26 May 2026
Basis for determining the amount to be paid
The issue price of ¥1,990 was determined based on the closing price of ¥2,073 on 20 April 2026, applying a 4.00% discount
| Item | Details |
|---|---|
| Type of issuance or disposal | Public offering of new shares (general offering), issuance of new shares through a third-party allotment, and offering of shares (offering through an over-allotment) |
| Number of shares to be issued or disposed of | Public offering of new shares: 51,304,400 shares (domestic general offering: 21,804,400 shares; international offering: 29,500,000 shares). Issuance of new shares through a third-party allotment: 7,695,600 shares (maximum). Offering of shares: 7,695,600 shares |
| Issue price and disposal price | Public offering issue price: ¥1,990 per share. Third-party allotment payment amount: ¥1,907.08 per share. Offering price: ¥1,990 per share |
| Total issue value | Public offering: ¥102,095,756,000. Third-party allotment: ¥14,676,124,848 (maximum) |
| Amount of funds to be raised | Total payment amount: public offering ¥97,841,595,152; third-party allotment ¥14,676,124,848 (maximum). Total estimated net proceeds: ¥111,565,720,000 (maximum) |
| Specific use of funds | Details Research and development in oncology, primarily clinical trials for enzomenib and nuvisertib / Amount ¥30,000 million / Scheduled timing of expenditures By the end of March 2029, Details Research and development in neurodegenerative diseases and infectious diseases / Amount ¥10,000 million / Scheduled timing of expenditures By the end of March 2029, Details Investments and loans to RACTHERA and S-RACMO / Amount ¥10,000 million / Scheduled timing of expenditures By the end of March 2029, Details Strategic investments in capital expenditures to strengthen production and quality systems, IT systems, and partnerships and licensing agreements relating to the development and sale of products manufactured by other companies / Amount ¥10,000 million / Scheduled timing of expenditures By the end of March 2029, Details Repayment of interest-bearing debt / Amount Remaining amount / Scheduled timing of expenditures By the end of March 2029 |
| Payment date | Public offering: 24 April 2026. Third-party allotment: 26 May 2026 |
| Intended allottee | Public offering: domestic underwriters and international underwriters. Third-party allotment: Not disclosed |
| Total number of issued shares | Issuance of 51,304,400 new shares through the public offering and 7,695,600 new shares through the third-party allotment (maximum) |
| Basis for determining the amount to be paid | The issue price of ¥1,990 was determined based on the closing price of ¥2,073 on 20 April 2026, applying a 4.00% discount |
| Underwriter / lead underwriter | Domestic underwriters and international underwriters (individual names: Not disclosed) |
| Overallotment | Shares offered: 7,695,600 shares. Maximum number of shares under the third-party allotment: 7,695,600 shares |
Items this document does not state (16)
Estimated issuance expensesIntended allottee's holding policyDilution RateExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company disclosed this information because the issue price, offering price and other terms have been determined. The proceeds are expected to be used for research and development in oncology and neurodegenerative diseases and infectious diseases, investments and loans for the regenerative medicine and cell therapy business, investments in production and quality systems, IT systems and partnerships, and repayment of interest-bearing debt.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.